
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$74.77
+US$1.69 · +2.31%
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
前收盤價
US$74.77
+US$1.69 · +2.31%
盤中時間採用ET。市場資料可能有所延遲。
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
日內區間
目前US$74.77
52週區間
目前US$74.77
盤中時間採用ET。市場資料可能有所延遲。
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
日內區間
目前US$74.77
52週區間
目前US$74.77
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 94.67億 USD | 92.56億 USD | 85.44億 USD | 80.8億 USD | 77.76億 USD |
| 銷貨成本 | 27.94億 USD | 28.6億 USD | 27.1億 USD | 26.04億 USD | 24.64億 USD |
| 毛利 | 66.73億 USD | 63.96億 USD | 58.34億 USD | 54.76億 USD | 53.12億 USD |
| 研究與開發 | 6.98億 USD | 6.86億 USD | 6.14億 USD | 5.39億 USD | 5.08億 USD |
| 銷售、一般及管理費用 | 23.78億 USD | 23.18億 USD | 21.51億 USD | 20.09億 USD | 20.01億 USD |
| 營業費用 | 30.76億 USD | 30.04億 USD | 27.65億 USD | 25.48億 USD | 25.09億 USD |
| 利息收入 | 9300萬 USD | 1.06億 USD | 1.05億 USD | 5000萬 USD | 600萬 USD |
| 利息支出 | 2.43億 USD | 2.42億 USD | 2.58億 USD | 2.37億 USD | 2.36億 USD |
| 折舊和攤銷 | 4.87億 USD | 4.97億 USD | 4.91億 USD | 4.65億 USD | 4.48億 USD |
| 營業利益 | 35.97億 USD | 33.92億 USD | 30.69億 USD | 29.28億 USD | 28.03億 USD |
| 淨利 | 26.73億 USD | 24.86億 USD | 23.44億 USD | 21.14億 USD | 20.37億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$87.33
上漲空間 16.80%年度分割調整後的每股現金分配。
US$2.00
2025年(完整年度)+100.0% 自從 2021
2026年(部分年度):US$1.59
US$1.00
2,021
US$1.30
2,022
US$1.50
2,023
US$1.728
2,024
US$2.00
2,025
US$1.59
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息即將實施 | 2026年10月30日 | US$0.53Quarterly | 2026年10月30日 | 2026年12月1日 |
股息 | 2026年7月20日 | US$0.53Quarterly | 2026年7月20日 | 2026年9月1日 |
股息 | 2026年4月20日 | US$0.53Quarterly | 2026年4月20日 | 2026年6月2日 |
股息 | 2026年1月20日 | US$0.53Quarterly | 2026年1月20日 | 2026年3月3日 |
股息 | 2025年10月31日 | US$0.50Quarterly | 2025年10月31日 | 2025年12月2日 |
股息 | 2025年7月18日 | US$0.50Quarterly | 2025年7月18日 | 2025年9月3日 |
除息 2026年10月30日
US$0.53
Quarterly
2026年10月30日登記 · 支付日 2026年12月1日
除息 2026年7月20日
US$0.53
Quarterly
2026年7月20日登記 · 支付日 2026年9月1日
除息 2026年4月20日
US$0.53
Quarterly
2026年4月20日登記 · 支付日 2026年6月2日
除息 2026年1月20日
US$0.53
Quarterly
2026年1月20日登記 · 支付日 2026年3月3日
除息 2025年10月31日
US$0.50
Quarterly
2025年10月31日登記 · 支付日 2025年12月2日
除息 2025年7月18日
US$0.50
Quarterly
2025年7月18日登記 · 支付日 2025年9月3日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T583.63億0.05%129.43兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI9.25億0.04%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO8.59億0.05%1.8兆 USD0.03%US$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO6.29億0.28%2264億 USD0.03%US$81.14+0.92%
iShares Core S&P 500 ETFIVV4.01億0.05%8964.4億 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY3.69億0.05%8172億 USD0.09%US$778.57+0.60%
Vanguard Morningstar Value ETFVTV2.78億0.11%2624億 USD0.03%US$220.59+0.44%
VanEck Morningstar Wide Moat ETFMOAT2.68億2.34%115.3億 USD0.46%US$108.74+0.32%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
VanEck Morningstar Wide Moat ETFMOATAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。